

# Young Su Noh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4408693/publications.pdf>

Version: 2024-02-01

6  
papers

138  
citations

1937685

4  
h-index

2053705

5  
g-index

6  
all docs

6  
docs citations

6  
times ranked

238  
citing authors

#	ARTICLE	IF	CITATIONS
1	RAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
2	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72.	2.0	22
3	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 370-381.	2.5	9
4	Caffeoyloxy-5,6-dihydro-4-methyl-(2H)-pyran-2-one isolated from the leaves of <i>Olinia usambarensis</i> attenuates LPS-induced inflammatory mediators by inactivating AP-1 and NF- $\kappa$ B. <i>Chemico-Biological Interactions</i> , 2019, 309, 108718.	4.0	3
5	Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3000-3000.	1.6	40
6	Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 173.	0.9	0